RankAlpha logo
Back to Rankings

RCUS

Arcus BiosciencesB
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
RCUS vs peer average
62/100
RCUS vs. peer average (B vs. C)
Grade spread
A 2 · B 2 · C 2 · D 2 · F 1
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

EXEL is the first available peer comparator.

Exelixis is a practical treatment-line comparator because cabozantinib remains an established RCC backbone and Arcus is using casdatifan plus cabozantinib in PEAK-1, making EXEL relevant for combination positioning and commercial bar-setting.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerEXELExelixis
RCUS
Arcus Biosciences
EXEL
Exelixis
Grade
B
A
Momentum
70
77
Value
41
65
Sentiment
58
49
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Constructive
Open Side-by-Side ComparisonCompare all

Grade position vs EXEL

RCUS / EXEL
Grade Position
In line
RCUS vs. peer average (B vs. C)
62/100
Momentum
70
EXEL
Value
41
EXEL
Sentiment
58
RCUS

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs RCUS
1
EXEL
EXEL
A
100/100
-1
2
MRK
MRK
B
80/100
Even
3
TLX
Telix Pharmaceuticals Ltd ADR
N/A
-
-
4
DNLI
Denali Therapeutics Inc Common
A
100/100
-1
5
TNGX
Tango Therapeutics Inc Common
D
40/100
+2
EXEL is the first peer returned for this comparison set.